Italian active pharmaceutical ingredients and contract development and manufacturing organization Olon has revealed plans to expand its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m ($29m) in a domestic biotech hub.
Olon said the expansion in India would “further expand its global platform for developing and producing potent and high potent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?